藥品參考
Zenocutuzumab
Zenocutuzumab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 藥物類別: Oncology
- 用途: non-small cell lung cancer
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- 常見劑型
- 注射劑
- 常見規格
- 20 mg/ml
- 商品名
- 1
- 國家與市場
- 1
用途
作用方式
Bispecific antibody that binds the extracellular domains of HER2 and HER3, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. It decreases cell proliferation and PI3K-AKT-mTOR signaling, and mediates antibody-dependent cellular cytotoxicity.
成人常用劑量（仿單摘要）
NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma or cholangiocarcinoma: 750 mg IV infusion over 4 hours every 2 weeks until disease progression or unacceptable toxicity
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid.
- 哺乳
- Unsafe No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
已通報的副作用
- Diarrhea
- Musculoskeletal pain
- Fatigue
- Nausea
- Infusion-related reactions
- Dyspnea
黑框警語
- Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception.
哪些人需要特別留意
- Serious and life-threatening infusion-related reactions, hypersensitivity and anaphylaxis can occur. Give in a setting with emergency resuscitation equipment and monitor during and for at least 1 hour after the first infusion.
- Serious and life-threatening ILD/pneumonitis can occur. Monitor for new or worsening pulmonary symptoms.
- Left ventricular dysfunction can occur. Evaluate LVEF before starting and monitor at regular intervals. It has not been studied in patients with LVEF below 50% or clinically significant cardiac disease.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
同類別的其他藥品
常見問題
What is Zenocutuzumab used for?
Zenocutuzumab is a medicine in the class oncology. It is used for Non-small cell lung cancer, Pancreatic cancer.
What side effects have been reported with Zenocutuzumab?
Diarrhea, Musculoskeletal pain, Fatigue, Nausea, Infusion-related reactions, Dyspnea. Serious warning: Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm.
Can Zenocutuzumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid. Breastfeeding: Unsafe. No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
What does Zenocutuzumab interact with?
MediHelp does not list a checked interaction for Zenocutuzumab yet. Always tell your pharmacist about every medicine you take.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
